Phasing out DEHP from plastic indwelling medical devices used for intensive care: Does it reduce the long-term attention deficit of critically ill children?

Attention Children Critical illness DEHP Medical devices Plasticizers

Journal

Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270

Informations de publication

Date de publication:
01 2022
Historique:
received: 26 07 2021
revised: 08 10 2021
accepted: 25 10 2021
pubmed: 6 11 2021
medline: 8 1 2022
entrez: 5 11 2021
Statut: ppublish

Résumé

Children who have been critically ill face long-term developmental impairments. Iatrogenic exposure to di(2-ethylhexyl)phthalate (DEHP), a plasticizer leaching from plastic indwelling medical devices used in the pediatric intensive care unit (PICU), has been associated with the pronounced attention deficit observed in children 4 years after critical illness. As concerns about DEHP toxicity increased, governmental authorities urged the phase out of DEHP in indwelling medical devices and replacement with alternative plasticizers. We hypothesized that exposure to DEHP decreased over the years, attenuating the pronounced long-term attention deficit of these vulnerable children. We compared plasma concentrations of 3 oxidative DEHP metabolites (5cx-MEPP, 5OH-MEHP, 5oxo-MEHP) on the last PICU day in 216 patients who participated in the Tight Glucose Control study (2004-2007) and 334 patients who participated in the PEPaNIC study (2012-2015) and survived PICU stay. Corresponding minimal exposures to these metabolites (plasma concentration multiplied with number of days in PICU) were also evaluated. In patients with 4-year follow-up data, we compared measures of attention (standardized reaction times and consistency). Comparisons were performed with univariable analyses and multivariable linear regression analyses adjusted for baseline risk factors. In the PEPaNIC patients, last PICU day plasma concentrations of 5cx-MEPP, 5OH-MEHP, 5oxo-MEHP and their sum, and corresponding minimal exposures, were reduced to 17-69% of those in the Tight Glucose Control study (p < 0.0001). Differences remained significant after multivariable adjustment (p ≤ 0.001). PEPaNIC patients did not show better attention than patients in the Tight Glucose Control study, also not after multivariable adjustment for risk factors. Exposure of critically ill children to DEHP in the PICU decreased over the years, but the lower exposure did not translate into improved attention 4 years later. Whether the residual exposure may still be toxic or whether the plasticizers replacing DEHP may not be safe for neurodevelopment needs further investigation.

Sections du résumé

BACKGROUND
Children who have been critically ill face long-term developmental impairments. Iatrogenic exposure to di(2-ethylhexyl)phthalate (DEHP), a plasticizer leaching from plastic indwelling medical devices used in the pediatric intensive care unit (PICU), has been associated with the pronounced attention deficit observed in children 4 years after critical illness. As concerns about DEHP toxicity increased, governmental authorities urged the phase out of DEHP in indwelling medical devices and replacement with alternative plasticizers. We hypothesized that exposure to DEHP decreased over the years, attenuating the pronounced long-term attention deficit of these vulnerable children.
METHODS
We compared plasma concentrations of 3 oxidative DEHP metabolites (5cx-MEPP, 5OH-MEHP, 5oxo-MEHP) on the last PICU day in 216 patients who participated in the Tight Glucose Control study (2004-2007) and 334 patients who participated in the PEPaNIC study (2012-2015) and survived PICU stay. Corresponding minimal exposures to these metabolites (plasma concentration multiplied with number of days in PICU) were also evaluated. In patients with 4-year follow-up data, we compared measures of attention (standardized reaction times and consistency). Comparisons were performed with univariable analyses and multivariable linear regression analyses adjusted for baseline risk factors.
RESULTS
In the PEPaNIC patients, last PICU day plasma concentrations of 5cx-MEPP, 5OH-MEHP, 5oxo-MEHP and their sum, and corresponding minimal exposures, were reduced to 17-69% of those in the Tight Glucose Control study (p < 0.0001). Differences remained significant after multivariable adjustment (p ≤ 0.001). PEPaNIC patients did not show better attention than patients in the Tight Glucose Control study, also not after multivariable adjustment for risk factors.
CONCLUSION
Exposure of critically ill children to DEHP in the PICU decreased over the years, but the lower exposure did not translate into improved attention 4 years later. Whether the residual exposure may still be toxic or whether the plasticizers replacing DEHP may not be safe for neurodevelopment needs further investigation.

Identifiants

pubmed: 34739923
pii: S0160-4120(21)00587-0
doi: 10.1016/j.envint.2021.106962
pmc: PMC8685605
pii:
doi:

Substances chimiques

Plasticizers 0
Plastics 0
Diethylhexyl Phthalate C42K0PH13C

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106962

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Int J Environ Res Public Health. 2020 Nov 04;17(21):
pubmed: 33158190
Food Chem Toxicol. 2019 Apr;126:152-161
pubmed: 30790713
Toxicol Lett. 2009 Aug 25;189(1):67-77
pubmed: 19463926
JAMA. 2012 Oct 24;308(16):1641-50
pubmed: 23101118
Environ Int. 2020 Oct;143:105894
pubmed: 32679391
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Feb 15;949-950:99-108
pubmed: 24480330
Toxicol Lett. 2011 Feb 25;201(1):34-41
pubmed: 21145954
Int J Pharm. 2011 May 16;409(1-2):57-61
pubmed: 21356303
Intensive Care Med. 2016 Mar;42(3):379-392
pubmed: 26667027
Environ Health Perspect. 2012 Feb;120(2):290-5
pubmed: 21893441
Environ Toxicol Pharmacol. 2016 Jan;41:62-71
pubmed: 26650799
Am J Kidney Dis. 2012 Apr;59(4):523-30
pubmed: 22206744
Regul Toxicol Pharmacol. 2016 Apr;76:209-10
pubmed: 26854686
Neurology. 2003 Dec 23;61(12):1779-82
pubmed: 14694046
Intensive Care Med. 2018 May;44(5):649-651
pubmed: 29063130
Psychol Med. 2015 Jun;45(8):1601-12
pubmed: 25388623
EFSA J. 2019 Dec 11;17(12):e05838
pubmed: 32626195
Toxicol Sci. 2011 Oct;123(2):460-70
pubmed: 21742782
Lancet Child Adolesc Health. 2020 Jul;4(7):503-514
pubmed: 32562632
Environ Int. 2015 Aug;81:64-72
pubmed: 25955314
Crit Care. 2020 Jun 16;24(1):347
pubmed: 32546247
Environ Health Perspect. 2018 May 10;126(5):057004
pubmed: 29790729
Toxicol Lett. 2018 May 1;287:83-91
pubmed: 29421333
J Biomed Mater Res B Appl Biomater. 2014 May;102(4):721-8
pubmed: 24155207
Environ Health Perspect. 2011 Oct;119(10):1495-500
pubmed: 21737372
Toxicol Lett. 2020 May 6;330:7-13
pubmed: 32387387
Environ Health Perspect. 2010 Apr;118(4):565-71
pubmed: 20106747
Chemosphere. 2020 Aug;252:126498
pubmed: 32197170
J Thorac Cardiovasc Surg. 2013 Feb;145(2):482-488.e2
pubmed: 22507845
Environ Sci Pollut Res Int. 2016 Dec;23(24):24642-24693
pubmed: 27714658
JPEN J Parenter Enteral Nutr. 2011 Nov;35(6):770-5
pubmed: 21868720
Endocr Rev. 2015 Dec;36(6):E1-E150
pubmed: 26544531
Food Chem Toxicol. 2002 Oct;40(10):1499-506
pubmed: 12387315
Environ Health Perspect. 2006 Sep;114(9):1424-31
pubmed: 16966100
Sci Total Environ. 2012 Aug 15;432:357-64
pubmed: 22750182
Environ Health Perspect. 2007 Dec;115 Suppl 1:51-4
pubmed: 18174950
Chemosphere. 2021 Nov;282:131013
pubmed: 34090004
Environ Res. 2014 Jan;128:64-9
pubmed: 24267794
Lancet Neurol. 2012 Sep;11(9):774-83
pubmed: 22863608
Lancet. 2009 Feb 14;373(9663):547-56
pubmed: 19176240
Front Neurosci. 2018 Jul 24;12:444
pubmed: 30087586
Biol Psychiatry. 2009 Nov 15;66(10):958-63
pubmed: 19748073
Sci Total Environ. 2020 Jan 10;699:134053
pubmed: 31678884
Chemosphere. 2019 Oct;233:590-596
pubmed: 31200129
Mol Cell Endocrinol. 2005 Dec 1;244(1-2):15-9
pubmed: 16223563
Environ Res. 2017 Jul;156:158-166
pubmed: 28342962
J Toxicol. 2021 Feb 9;2021:8815202
pubmed: 33628236
Toxicol Lett. 2015 Oct 14;238(2):100-9
pubmed: 26211741
Environ Health Perspect. 2010 Jul;118(7):1027-32
pubmed: 20194078
Toxicol Sci. 2019 Mar 1;168(1):78-94
pubmed: 30398665
PLoS One. 2015 Jun 29;10(6):e0131910
pubmed: 26121592
Indian J Med Res. 2004 Apr;119(4):139-44
pubmed: 15147118
Environ Pollut. 2017 Oct;229:375-385
pubmed: 28614761
Pediatr Crit Care Med. 2018 Apr;19(4):298-300
pubmed: 29406379
Lancet Respir Med. 2019 Feb;7(2):141-153
pubmed: 30224325
J Hazard Mater. 2019 Feb 5;363:64-72
pubmed: 30308366
Early Hum Dev. 2014 Sep;90(9):477-85
pubmed: 25038557
N Engl J Med. 2016 Mar 24;374(12):1111-22
pubmed: 26975590
Sci Total Environ. 2018 May 15;624:377-384
pubmed: 29258038
Environ Health Perspect. 2005 Sep;113(9):1222-5
pubmed: 16140631

Auteurs

Ilse Vanhorebeek (I)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium. Electronic address: ilse.vanhorebeek@kuleuven.be.

Govindan Malarvannan (G)

Toxicological Center, University of Antwerp, Wilrijk, Belgium.

Fabian Güiza (F)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Giulia Poma (G)

Toxicological Center, University of Antwerp, Wilrijk, Belgium.

Inge Derese (I)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Pieter J Wouters (PJ)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Koen Joosten (K)

Intensive Care Unit, Department of Pediatrics and Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, the Netherlands.

Sascha Verbruggen (S)

Intensive Care Unit, Department of Pediatrics and Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, the Netherlands.

Philippe G Jorens (PG)

Department of Intensive Care Medicine and Clinical Pharmacology, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.

Adrian Covaci (A)

Toxicological Center, University of Antwerp, Wilrijk, Belgium.

Greet Van den Berghe (G)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH